Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biophytis Sa ADR
(NQ:
BPTS
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biophytis Sa ADR
< Previous
1
2
3
Next >
Biophytis: Convening of Another Combined General Meeting at a Later Date
June 03, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June
May 12, 2022
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 12, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022
April 19, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 19, 2022 / Biophytis SA ((NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives
April 07, 2022
- Success of Nasdaq IPO in February 2021 - €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 - Strong growth...
From
Biophytis
Via
AccessWire
Topics
Initial Public Offering
Exposures
COVID-19
Securities Market
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development
April 07, 2022
- Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia, with the objective of having a First Patient In by end of H2 2022 - COVID-19 (COVA): 237...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Product Safety
Biophytis Appoints Philippe Rousseau as Chief Financial Officer
April 05, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 5, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized...
From
Biophytis
Via
AccessWire
Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly
March 16, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 16,2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program
February 03, 2022
- ANVISA (Brazilian Health Authority) approved Biophytis' Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care Unit - Sarconeos...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for €3 Million
December 22, 2021
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / December 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), a clinical-stage biotechnology company focused on the development of...
From
Biophytis
Via
AccessWire
Topics
Bonds
Exposures
Debt Markets
Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3
December 16, 2021
- Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 development - A Type B/End-of-Phase 2 meeting is planned...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Product Safety
Biophytis Obtains a New 10M€ Loan Structure With Kreos Capital
November 22, 2021
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company...
From
Biophytis
Via
AccessWire
Topics
Bonds
Regulatory Compliance
Exposures
COVID-19
Debt Markets
Legal
Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19
November 15, 2021
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 15, 2021 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company...
From
Biophytis
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021
October 29, 2021
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 29, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused...
From
Biophytis
Via
AccessWire
Topics
Bonds
Derivatives
Regulatory Compliance
Exposures
COVID-19
Debt Markets
Derivatives
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.